Last reviewed 2026-05-19 · How we verify

PF-08052667 (pf-08052667)

Pfizer Inc. · FDA-approved active ✓ Verified May 2026 Quality 3/100

PF-08052667 (generic name: pf-08052667) is a drug developed by Pfizer Inc.. It is currently FDA-approved.

PF-08052667 is a study medicine being evaluated in a Phase 1 clinical trial for Non-muscle Invasive Bladder Cancer. The trial is assessing the safety, tolerability, pharmacokinetics, and antitumor activity of PF-08052667 in combination with Sasanlimab and BCG.

At a glance

Generic name	pf-08052667
Sponsor	Pfizer Inc.
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-08052667 CI brief — competitive landscape report
PF-08052667 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about PF-08052667

What is PF-08052667?

PF-08052667 (pf-08052667) is a pharmaceutical drug developed by Pfizer Inc..

Who makes PF-08052667?

PF-08052667 is developed and marketed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of PF-08052667?

pf-08052667 is the generic (nonproprietary) name of PF-08052667.

What development phase is PF-08052667 in?

PF-08052667 is FDA-approved (marketed).

Manufacturer: Pfizer Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing